Marinomed Biotech AG Stock

Equities

MARI

ATMARINOMED6

Pharmaceuticals

Market Closed - Wiener Boerse 11:37:15 2024-06-07 am EDT 5-day change 1st Jan Change
13.25 EUR +3.52% Intraday chart for Marinomed Biotech AG -5.36% -54.62%
Sales 2024 * 18.19M 19.6M Sales 2025 * 24.58M 26.49M Capitalization 20.41M 22M
Net income 2024 * - 0 Net income 2025 * 2M 2.16M EV / Sales 2024 * 2.06 x
Net Debt 2024 * 17.11M 18.44M Net Debt 2025 * 13.53M 14.58M EV / Sales 2025 * 1.38 x
P/E ratio 2024 *
42.7 x
P/E ratio 2025 *
9.64 x
Employees 44
Yield 2024 *
-
Yield 2025 *
-
Free-Float 65.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.52%
1 week-5.36%
Current month-5.36%
1 month-22.51%
3 months-38.08%
6 months-60.21%
Current year-54.62%
More quotes
1 week
12.30
Extreme 12.3
14.15
1 month
12.30
Extreme 12.3
17.35
Current year
12.30
Extreme 12.3
32.00
1 year
12.30
Extreme 12.3
45.50
3 years
12.30
Extreme 12.3
127.00
5 years
12.30
Extreme 12.3
147.00
10 years
12.30
Extreme 12.3
147.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 05-12-31
Founder 56 05-12-31
Director of Finance/CFO 52 18-07-31
Members of the board TitleAgeSince
Chairman 58 07-12-31
Director/Board Member 68 18-11-20
Director/Board Member - 22-06-14
More insiders
Date Price Change Volume
24-06-07 13.25 +3.52% 6,366
24-06-06 12.8 -0.78% 2,486
24-06-05 12.9 -4.80% 2,604
24-06-04 13.55 -0.73% 2,570
24-06-03 13.65 -2.50% 5,945

Delayed Quote Wiener Boerse, June 07, 2024 at 11:37 am EDT

More quotes
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
13.25 EUR
Average target price
63 EUR
Spread / Average Target
+375.47%
Consensus

Annual profits - Rate of surprise